24/7 Market News Snapshot 02 October, 2025 – Kazia Therapeutics Limited American Depositary Shares (NASDAQ:KZIA)

October 2, 2025

DENVER, Colo., 02 October, 2025 (www.247marketnews.com) – (NASDAQ:KZIA) are discussed in this article.
Kazia Therapeutics Limited has recently demonstrated a notable upward trend in its stock performance, currently trading at $6.875, a 0.36% increase from the prior closing of $6.850. This uptick is underscored by a robust trading volume of 2.20 million shares, suggesting heightened interest from investors. The stock’s momentum indicates positive market sentiment, potentially driven by significant developments tied to the company’s research activities. Analysts are advising traders to keep an eye on key resistance levels around $7.00 and support near $6.50. Continued trading volume surpassing average levels may reinforce the bullish outlook, hinting at further price growth as market conditions evolve.

In addition to its stock performance, Kazia Therapeutics has made headlines with groundbreaking results from a single-patient expanded access case involving its investigational drug, paxalisib. This case involved a 40-plus-year-old female patient diagnosed with triple-negative breast cancer (TNBC), who exhibited a remarkable 86% reduction in overall tumor burden after just three weeks of treatment. The patient, who had undergone a comprehensive treatment approach including chemotherapy and immunotherapy, faced a metastatic diagnosis affecting bone and lungs. The promising results from this case highlight the potential of paxalisib to enhance therapeutic responses in advanced TNBC and are aligned with the objectives of Kazia’s ongoing Phase 1b trial.

Dr. John Friend, CEO of Kazia, noted the significance of the rapid and substantial tumor regression, which supports the company’s rationale for integrating paxalisib with immune checkpoint blockade. The company remains steadfast in advancing its clinical trials and exploring the drug’s efficacy across various cancer indications, underscoring its commitment to developing innovative treatments for patients battling complex malignancies. Kazia’s dedication is further reinforced by receiving Orphan Drug and Fast Track Designations from the FDA, enhancing its strategic position in the oncology landscape.

Related news for (KZIA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.